Biscayne Pharmaceuticals Receives Funding Through Florida Institute Seed Capital Accelerator Program
Company Based on Technology Developed at the University of Miami
The Institute finalized a funding agreement through its Seed Capital Accelerator Program with Biscayne Pharmaceuticals, a startup biopharmaceutical company engaged in advancing commercial drug development. The company, based on technology licensed from the University of Miami, is discovering and developing novel therapies based on growth hormone-releasing hormone (GHRH) analogs. The company’s technology stems from the discoveries of Dr. Andrew V. Schally, a Nobel laureate and pioneering endocrine drug developer and initial disease targets include cancer, heart disease and other medical conditions where these therapies may prove effective.